# JULIET (NCT02445248)

> Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients

No report yet. It can be ordered.

- Drugs tested: tisagenlecleucel
- Indication: adult relapsed/refractory diffuse large B-cell lymphoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02445248
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Novartis Pharmaceuticals
- Conditions: Diffuse Large B-cell Lymphoma (DLBCL)
- Interventions: Tisagenlecleucel; Lymphodepleting chemotherapy
- Enrollment: 115
- Primary outcome: Overall Response Rate (ORR) Per Independent Review Committee (IRC) in Main Cohort

## Indexed commentary on JULIET so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=juliet-nct02445248